There Is a Risk of Spread During a Nebulization Session in a Patient with COVID-19.

IF 2 4区 医学 Q3 RESPIRATORY SYSTEM Journal of Aerosol Medicine and Pulmonary Drug Delivery Pub Date : 2023-10-01 Epub Date: 2023-08-22 DOI:10.1089/jamp.2023.0010
Christophe Thibon, Laurent Vecellio, Leila Belkhir, Jean-Christophe Dubus, Annie Robert, Benoît Kabamba, Gregory Reychler
{"title":"There Is a Risk of Spread During a Nebulization Session in a Patient with COVID-19.","authors":"Christophe Thibon,&nbsp;Laurent Vecellio,&nbsp;Leila Belkhir,&nbsp;Jean-Christophe Dubus,&nbsp;Annie Robert,&nbsp;Benoît Kabamba,&nbsp;Gregory Reychler","doi":"10.1089/jamp.2023.0010","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> A hypothetical risk of SARS-CoV-2 airborne transmission through nebulization was suggested based on a potential environmental contamination by the fugitive aerosol emitted in the environment during the procedure. The aim of this study was to verify this risk from the fugitive aerosol emitted by COVID-19 patients during one nebulization session. <b><i>Methods:</i></b> In this cohort study, COVID-19 patients treated with nebulization were recruited at their admission to the hospital. Patients had to perform a nebulization session while a BioSampler<sup>®</sup> and a pump were used to vacuum the fugitive aerosol and collect it for SARS-CoV-2 RNA detection. <b><i>Results:</i></b> Ten consecutive patients hospitalized with COVID-19 were recruited. The median viral load was 6.5 × 10<sup>6</sup> copies/mL. Two out of the 10 samples from the fugitive aerosol collected were positive to SARS-CoV-2. <b><i>Conclusion:</i></b> The risk of fugitive aerosol contamination with SARS-CoV-2 during nebulization has now been verified.</p>","PeriodicalId":14940,"journal":{"name":"Journal of Aerosol Medicine and Pulmonary Drug Delivery","volume":" ","pages":"268-274"},"PeriodicalIF":2.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Aerosol Medicine and Pulmonary Drug Delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/jamp.2023.0010","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: A hypothetical risk of SARS-CoV-2 airborne transmission through nebulization was suggested based on a potential environmental contamination by the fugitive aerosol emitted in the environment during the procedure. The aim of this study was to verify this risk from the fugitive aerosol emitted by COVID-19 patients during one nebulization session. Methods: In this cohort study, COVID-19 patients treated with nebulization were recruited at their admission to the hospital. Patients had to perform a nebulization session while a BioSampler® and a pump were used to vacuum the fugitive aerosol and collect it for SARS-CoV-2 RNA detection. Results: Ten consecutive patients hospitalized with COVID-19 were recruited. The median viral load was 6.5 × 106 copies/mL. Two out of the 10 samples from the fugitive aerosol collected were positive to SARS-CoV-2. Conclusion: The risk of fugitive aerosol contamination with SARS-CoV-2 during nebulization has now been verified.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新冠肺炎患者雾化治疗期间存在传播风险。
引言:根据手术过程中环境中散发的逃逸气溶胶对环境的潜在污染,提出了通过雾化传播严重急性呼吸系统综合征冠状病毒2型的假设风险。本研究的目的是验证新冠肺炎患者在一次雾化过程中释放的逃逸气溶胶的风险。方法:在这项队列研究中,招募接受雾化治疗的新冠肺炎患者入院。患者必须进行雾化治疗,同时使用BioSampler®和泵对逃逸气溶胶进行真空吸尘,并收集其进行严重急性呼吸系统综合征冠状病毒2型RNA检测。结果:招募了连续10名新冠肺炎住院患者。病毒载量中位数为6.5 × 106拷贝/mL。从逃逸气溶胶中采集的10个样本中,有两个对严重急性呼吸系统综合征冠状病毒2型呈阳性。结论:雾化过程中出现严重急性呼吸系统综合征冠状病毒2型无组织气溶胶污染的风险现已得到证实。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.70
自引率
2.90%
发文量
34
审稿时长
>12 weeks
期刊介绍: Journal of Aerosol Medicine and Pulmonary Drug Delivery is the only peer-reviewed journal delivering innovative, authoritative coverage of the health effects of inhaled aerosols and delivery of drugs through the pulmonary system. The Journal is a forum for leading experts, addressing novel topics such as aerosolized chemotherapy, aerosolized vaccines, methods to determine toxicities, and delivery of aerosolized drugs in the intubated patient. Journal of Aerosol Medicine and Pulmonary Drug Delivery coverage includes: Pulmonary drug delivery Airway reactivity and asthma treatment Inhalation of particles and gases in the respiratory tract Toxic effects of inhaled agents Aerosols as tools for studying basic physiologic phenomena.
期刊最新文献
In Vitro Comparison of Inspiration-Synchronized and Continuous Vibrating Mesh Nebulizer During Adult Invasive Mechanical Ventilation. Prospects of Inhalable Formulations of Conventionally Administered Repurposed Drugs for Adjunctive Treatment of Drug-Resistant Tuberculosis: Supporting Evidence from Clinical Trials and Cohort Studies. Scale-Up and Postapproval Changes in Orally Inhaled Drug Products: Scientific and Regulatory Considerations. Assessing Human Lung Pharmacokinetics Using Exhaled Breath Particles. Demographic and Asthma-Related Characteristics of Asthmatics Using Pressurized Metered Dose Inhalers and Dry Powder Inhalers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1